{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:10:21Z","timestamp":1794276621937,"version":"4.9.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515012593"],"award-info":[{"award-number":["2021A1515012593"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373129"],"award-info":[{"award-number":["82373129"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172750"],"award-info":[{"award-number":["82172750"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515111212"],"award-info":[{"award-number":["2022A1515111212"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Program of Guangzhou","award":["2023A04J1257"],"award-info":[{"award-number":["2023A04J1257"]}]},{"name":"Hunan Youth Science and Technology Talent Project","award":["NO.2023RC3074"],"award-info":[{"award-number":["NO.2023RC3074"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04183-y","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T19:02:06Z","timestamp":1749409326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibitors"],"prefix":"10.1186","volume":"23","author":[{"given":"Anqi","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihaoyun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaoqu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"4183_CR1","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.2147\/JIR.S379016","volume":"15","author":"A Lin","year":"2022","unstructured":"Lin A, Fang J, Cheng Q, Liu Z, Luo P, Zhang J. B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis. J Inflamm Res. 2022;15:5541\u201355.","journal-title":"J Inflamm Res"},{"key":"4183_CR2","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2147\/JIR.S394894","volume":"16","author":"A Lin","year":"2023","unstructured":"Lin A, Yao J, Cheng Q, Liu Z, Luo P, Zhang J. Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer. J Inflamm Res. 2023;16:1693\u2013709.","journal-title":"J Inflamm Res"},{"key":"4183_CR3","doi-asserted-by":"publisher","unstructured":"Fang Y, Kong Y, Rong G, Luo Q, Liao W, Zeng D. Systematic Investigation of Tumor Microenvironment and Antitumor Immunity With IOBR. Med Research. https:\/\/doi.org\/10.1002\/mdr2.70001.","DOI":"10.1002\/mdr2.70001"},{"key":"4183_CR4","volume":"22","author":"DL Nielsen","year":"2024","unstructured":"Nielsen DL, Juhl CB, Nielsen OH, Chen IM, Herrmann J. Immune Checkpoint Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis. JAMA Oncol. 2024Aug;22: e243065.","journal-title":"JAMA Oncol"},{"issue":"2","key":"4183_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","volume":"175","author":"MF Sanmamed","year":"2018","unstructured":"Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 2018Oct 4;175(2):313\u201326.","journal-title":"Cell"},{"issue":"3","key":"4183_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018Mar;18(3):153\u201367.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"4183_CR7","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1158\/2326-6066.CIR-24-0894","volume":"13","author":"L Huang","year":"2025","unstructured":"Huang L, Zhang C, Jiang A, Lin A, Zhu L, Mou W, et al. T-cell Senescence in the Tumor Microenvironment. Cancer Immunol Res. 2025May 2;13(5):618\u201332.","journal-title":"Cancer Immunol Res"},{"key":"4183_CR8","doi-asserted-by":"crossref","unstructured":"Jiang A, Li J, He Z, Liu Y, Qiao K, Fang Y, et al. Renal cancer: signaling pathways and advances in targeted therapies. MedComm (2020). 2024 Aug;5(8):e676.","DOI":"10.1002\/mco2.676"},{"key":"4183_CR9","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3389\/fphar.2020.01213","volume":"11","author":"Y Niu","year":"2020","unstructured":"Niu Y, Lin A, Luo P, Zhu W, Wei T, Tang R, et al. Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors. Front Pharmacol. 2020;11:1213.","journal-title":"Front Pharmacol"},{"issue":"7\u20138","key":"4183_CR10","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41417-020-0207-6","volume":"28","author":"W Huang","year":"2021","unstructured":"Huang W, Lin A, Luo P, Liu Y, Xu W, Zhu W, et al. EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma. Cancer Gene Ther. 2021Aug;28(7\u20138):864\u201374.","journal-title":"Cancer Gene Ther"},{"key":"4183_CR11","doi-asserted-by":"publisher","first-page":"1447021","DOI":"10.3389\/fimmu.2024.1447021","volume":"15","author":"S Keam","year":"2024","unstructured":"Keam S, Turner N, Kugeratski FG, Rico R, Colunga-Minutti J, Poojary R, et al. Toxicity in the era of immune checkpoint inhibitor therapy. Front Immunol. 2024;15:1447021.","journal-title":"Front Immunol"},{"issue":"59","key":"4183_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101967","volume":"21","author":"C Zhou","year":"2023","unstructured":"Zhou C, Peng S, Lin A, Jiang A, Peng Y, Gu T, et al. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. EClinicalMedicine. 2023Apr;21(59): 101967.","journal-title":"EClinicalMedicine"},{"issue":"2","key":"4183_CR13","doi-asserted-by":"publisher","first-page":"E40","DOI":"10.1503\/cmaj.180870","volume":"191","author":"K Esfahani","year":"2019","unstructured":"Esfahani K, Meti N, Miller WH, Hudson M. Adverse events associated with immune checkpoint inhibitor treatment for cancer. CMAJ. 2019Jan 14;191(2):E40\u20136.","journal-title":"CMAJ"},{"issue":"10","key":"4183_CR14","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jamadermatol.2023.3003","volume":"159","author":"Y Du","year":"2023","unstructured":"Du Y, Wu W, Chen M, Dong Z, Wang F. Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment: A Systematic Review and Meta-Analysis. JAMA Dermatol. 2023Oct 1;159(10):1093\u2013101.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"4183_CR15","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41568-024-00715-5","volume":"24","author":"AZ Munir","year":"2024","unstructured":"Munir AZ, Gutierrez A, Qin J, Lichtman AH, Moslehi JJ. Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart. Nat Rev Cancer. 2024Aug;24(8):540\u201353.","journal-title":"Nat Rev Cancer"},{"key":"4183_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102684","volume":"73","author":"J Shen","year":"2024","unstructured":"Shen J, Hu R, Lin A, Jiang A, Tang B, Liu Z, et al. Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase. EClinicalMedicine. 2024Jul;73: 102684.","journal-title":"EClinicalMedicine"},{"issue":"3","key":"4183_CR17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/ijc.34332","volume":"152","author":"T Gu","year":"2023","unstructured":"Gu T, Jiang A, Zhou C, Lin A, Cheng Q, Liu Z, et al. Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis. Int J Cancer. 2023Feb 1;152(3):480\u201395.","journal-title":"Int J Cancer"},{"issue":"10","key":"4183_CR18","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.3390\/cancers14102429","volume":"14","author":"A Di Federico","year":"2022","unstructured":"Di Federico A, Mosca M, Pagani R, Carloni R, Frega G, De Giglio A, et al. Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. Cancers (Basel). 2022May 14;14(10):2429.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"4183_CR19","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41568-022-00513-x","volume":"22","author":"MR Fernandes","year":"2022","unstructured":"Fernandes MR, Aggarwal P, Costa RGF, Cole AM, Trinchieri G. Targeting the gut microbiota for cancer therapy. Nat Rev Cancer. 2022Dec;22(12):703\u201322.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"4183_CR20","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1158\/2159-8290.CD-21-0236","volume":"11","author":"L Derosa","year":"2021","unstructured":"Derosa L, Routy B, Desilets A, Daill\u00e8re R, Terrisse S, Kroemer G, et al. Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology? Cancer Discov. 2021Oct;11(10):2396\u2013412.","journal-title":"Cancer Discov"},{"issue":"Pt 3","key":"4183_CR21","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.semcancer.2021.09.007","volume":"86","author":"A Rizzo","year":"2022","unstructured":"Rizzo A, Santoni M, Mollica V, Fiorentino M, Brandi G, Massari F. Microbiota and prostate cancer. Semin Cancer Biol. 2022Nov;86(Pt 3):1058\u201365.","journal-title":"Semin Cancer Biol"},{"key":"4183_CR22","doi-asserted-by":"crossref","unstructured":"Liu L, Xie Y, Yang H, Lin A, Dong M, Wang H, et al. HPVTIMER: A shiny web application for tumor immune estimation in human papillomavirus\u2010associated cancers. iMeta. 2023 Aug;2(3):e130.","DOI":"10.1002\/imt2.130"},{"issue":"115","key":"4183_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105708","volume":"22","author":"Y Situ","year":"2025","unstructured":"Situ Y, Zhang P, Zhang C, Jiang A, Zhang N, Zhu L, et al. The metabolic dialogue between intratumoural microbes and cancer: implications for immunotherapy. EBioMedicine. 2025Apr;22(115): 105708.","journal-title":"EBioMedicine"},{"key":"4183_CR24","doi-asserted-by":"crossref","unstructured":"Mou W, Deng Z, Zhu L, Jiang A, Lin A, Xu L, et al. Intratumoral Mycobiome Heterogeneity Influences the Tumor Microenvironment and Immunotherapy Outcomes in Renal Cell Carcinoma. Sci Adv. 2025 Apr 11;11(15):eadu1727.","DOI":"10.1126\/sciadv.adu1727"},{"key":"4183_CR25","doi-asserted-by":"publisher","unstructured":"Gao Z, Jiang A, Li Z, Zhu L, Mou W, Shen W, et al. Heterogeneity of intratumoral microbiota within the tumor microenvironment and relationship to tumor development. Med Research. https:\/\/doi.org\/10.1002\/mdr2.70006.","DOI":"10.1002\/mdr2.70006"},{"issue":"4","key":"4183_CR26","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.eururo.2020.07.011","volume":"78","author":"NJ Salgia","year":"2020","unstructured":"Salgia NJ, Bergerot PG, Maia MC, Dizman N, Hsu J, Gillece JD, et al. Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti-PD-1 Immune Checkpoint Inhibitors. Eur Urol. 2020Oct;78(4):498\u2013502.","journal-title":"Eur Urol"},{"issue":"10","key":"4183_CR27","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1158\/2326-6066.CIR-20-0196","volume":"8","author":"T Hakozaki","year":"2020","unstructured":"Hakozaki T, Richard C, Elkrief A, Hosomi Y, Benla\u00effaoui M, Mimpen I, et al. The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer. Cancer Immunol Res. 2020Oct;8(10):1243\u201350.","journal-title":"Cancer Immunol Res"},{"issue":"6371","key":"4183_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018Jan 5;359(6371):97\u2013103.","journal-title":"Science"},{"issue":"2","key":"4183_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","volume":"28","author":"L Derosa","year":"2022","unstructured":"Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med. 2022Feb;28(2):315\u201324.","journal-title":"Nat Med"},{"issue":"6371","key":"4183_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018Jan 5;359(6371):91\u20137.","journal-title":"Science"},{"key":"4183_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.104967","volume":"100","author":"Y Yang","year":"2024","unstructured":"Yang Y, An Y, Dong Y, Chu Q, Wei J, Wang B, et al. Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy. EBioMedicine. 2024Feb;100: 104967.","journal-title":"EBioMedicine"},{"issue":"598","key":"4183_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217123","volume":"28","author":"L Xia","year":"2024","unstructured":"Xia L, Zhu X, Wang Y, Lu S. The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect. Cancer Lett. 2024Aug;28(598): 217123.","journal-title":"Cancer Lett"},{"issue":"1","key":"4183_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13073-022-01037-7","volume":"14","author":"RC Newsome","year":"2022","unstructured":"Newsome RC, Gharaibeh RZ, Pierce CM, da Silva WV, Paul S, Hogue SR, et al. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort. Genome Med. 2022Mar 29;14(1):35.","journal-title":"Genome Med"},{"issue":"6529","key":"4183_CR34","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","volume":"371","author":"EN Baruch","year":"2021","unstructured":"Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021Feb 5;371(6529):602\u20139.","journal-title":"Science"},{"issue":"6529","key":"4183_CR35","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021Feb 5;371(6529):595\u2013602.","journal-title":"Science"},{"issue":"7","key":"4183_CR36","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1158\/2159-8290.CD-24-0066","volume":"14","author":"IC Glitza","year":"2024","unstructured":"Glitza IC, Seo YD, Spencer CN, Wortman JR, Burton EM, Alayli FA, et al. Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity. Cancer Discov. 2024Jul 1;14(7):1161\u201375.","journal-title":"Cancer Discov"},{"issue":"1","key":"4183_CR37","doi-asserted-by":"publisher","first-page":"2452277","DOI":"10.1080\/19490976.2025.2452277","volume":"17","author":"A Lin","year":"2025","unstructured":"Lin A, Jiang A, Huang L, Li Y, Zhang C, Zhu L, et al. From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy. Gut Microbes. 2025Dec;17(1):2452277.","journal-title":"Gut Microbes"},{"issue":"366","key":"4183_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"28","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019Aug;28(366): l4898.","journal-title":"BMJ"},{"issue":"355","key":"4183_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"12","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016Oct;12(355): i4919.","journal-title":"BMJ"},{"issue":"4","key":"4183_CR40","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","volume":"16","author":"L Furuya-Kanamori","year":"2018","unstructured":"Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid Based Healthc. 2018Dec;16(4):195\u2013203.","journal-title":"Int J Evid Based Healthc"},{"key":"4183_CR41","doi-asserted-by":"crossref","unstructured":"Duttagupta S, Messaoudene M, Jamal R, Mihalcioiu C, Belanger K, Lenehan J, et al. Abstract CT258: Phase II trial of fecal microbiota transplantation in combination with ipilimumab and nivolumab in patients with advanced cutaneous melanoma (FMT-LUMINate trial). Cancer Research. 2024 Apr 5;84(7_Supplement):CT258.","DOI":"10.1158\/1538-7445.AM2024-CT258"},{"key":"4183_CR42","doi-asserted-by":"crossref","unstructured":"Fernandes R, Parvathy SN, Ernst DS, Haeryfar M, Burton J, Silverman M, et al. Preventing adverse events in patients with renal cell carcinoma treated with doublet immunotherapy using fecal microbiota transplantation (FMT): Initial results from perform a phase I study. JCO. 2022 Jun;40(16_suppl):4553\u20134553.","DOI":"10.1200\/JCO.2022.40.16_suppl.4553"},{"issue":"8","key":"4183_CR43","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.chom.2024.06.010","volume":"32","author":"Y Kim","year":"2024","unstructured":"Kim Y, Kim G, Kim S, Cho B, Kim SY, Do EJ, et al. Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor. Cell Host Microbe. 2024Aug 14;32(8):1380-1393.e9.","journal-title":"Cell Host Microbe"},{"issue":"4","key":"4183_CR44","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","volume":"28","author":"N Dizman","year":"2022","unstructured":"Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med. 2022Apr;28(4):704\u201312.","journal-title":"Nat Med"},{"issue":"8","key":"4183_CR45","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","volume":"29","author":"B Routy","year":"2023","unstructured":"Routy B, Lenehan JG, Miller WH, Jamal R, Messaoudene M, Daisley BA, et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat Med. 2023Aug;29(8):2121\u201332.","journal-title":"Nat Med"},{"issue":"6","key":"4183_CR46","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.annonc.2023.02.011","volume":"34","author":"A Spreafico","year":"2023","unstructured":"Spreafico A, Heirali AA, Araujo DV, Tan TJ, Oliva M, Schneeberger PHH, et al. First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial). Ann Oncol. 2023Jun 1;34(6):520\u201330.","journal-title":"Ann Oncol"},{"key":"4183_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102315","volume":"66","author":"W Zhao","year":"2023","unstructured":"Zhao W, Lei J, Ke S, Chen Y, Xiao J, Tang Z, et al. Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215). EClinicalMedicine. 2023Dec;66: 102315.","journal-title":"EClinicalMedicine"},{"issue":"3","key":"4183_CR48","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41591-024-02803-3","volume":"30","author":"JR Bj\u00f6rk","year":"2024","unstructured":"Bj\u00f6rk JR, Bolte LA, Maltez Thomas A, Lee KA, Rossi N, Wind TT, et al. Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma. Nat Med. 2024Mar;30(3):785\u201396.","journal-title":"Nat Med"},{"issue":"4","key":"4183_CR49","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.chom.2024.03.002","volume":"32","author":"X Zhu","year":"2024","unstructured":"Zhu X, Huang X, Hu M, Sun R, Li J, Wang H, et al. A specific enterotype derived from gut microbiome of older individuals enables favorable responses to immune checkpoint blockade therapy. Cell Host Microbe. 2024Apr 10;32(4):489-505.e5.","journal-title":"Cell Host Microbe"},{"issue":"7","key":"4183_CR50","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.chom.2023.05.024","volume":"31","author":"C Frioux","year":"2023","unstructured":"Frioux C, Ansorge R, \u00d6zkurt E, Ghassemi Nedjad C, Fritscher J, Quince C, et al. Enterosignatures define common bacterial guilds in the human gut microbiome. Cell Host Microbe. 2023Jul 12;31(7):1111-1125.e6.","journal-title":"Cell Host Microbe"},{"issue":"7346","key":"4183_CR51","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/nature09944","volume":"473","author":"M Arumugam","year":"2011","unstructured":"Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. 2011May 12;473(7346):174\u201380.","journal-title":"Nature"},{"issue":"12","key":"4183_CR52","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/iub.2908","volume":"76","author":"S Zuo","year":"2024","unstructured":"Zuo S, Huang Y, Zou J. The role of the gut microbiome in modulating immunotherapy efficacy in colorectal cancer. IUBMB Life. 2024Dec;76(12):1050\u20137.","journal-title":"IUBMB Life"},{"issue":"6371","key":"4183_CR53","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018Jan 5;359(6371):104\u20138.","journal-title":"Science"},{"key":"4183_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.669150","volume":"12","author":"J Wu","year":"2021","unstructured":"Wu J, Wang S, Zheng B, Qiu X, Wang H, Chen L. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy. Front Immunol. 2021;12: 669150.","journal-title":"Front Immunol"},{"issue":"6264","key":"4183_CR55","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015Nov 27;350(6264):1084\u20139.","journal-title":"Science"},{"issue":"6371","key":"4183_CR56","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018Jan 5;359(6371):104\u20138.","journal-title":"Science"},{"issue":"5","key":"4183_CR57","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s00262-022-03329-8","volume":"72","author":"M Ninkov","year":"2023","unstructured":"Ninkov M, Schmerk CL, Moradizadeh M, Parvathy SN, Figueredo R, Burton JP, et al. Improved MAIT cell functions following fecal microbiota transplantation for metastatic renal cell carcinoma. Cancer Immunol Immunother. 2023May;72(5):1247\u201360.","journal-title":"Cancer Immunol Immunother"},{"key":"4183_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.874922","volume":"13","author":"J Huang","year":"2022","unstructured":"Huang J, Zheng X, Kang W, Hao H, Mao Y, Zhang H, et al. Metagenomic and metabolomic analyses reveal synergistic effects of fecal microbiota transplantation and anti-PD-1 therapy on treating colorectal cancer. Front Immunol. 2022;13: 874922.","journal-title":"Front Immunol"},{"issue":"1","key":"4183_CR59","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12943-023-01722-0","volume":"22","author":"Z Gao","year":"2023","unstructured":"Gao Z, Bai Y, Lin A, Jiang A, Zhou C, Cheng Q, et al. Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment. Mol Cancer. 2023Feb 15;22(1):31.","journal-title":"Mol Cancer"},{"issue":"1","key":"4183_CR60","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-024-01972-6","volume":"23","author":"S Peng","year":"2024","unstructured":"Peng S, Lin A, Jiang A, Zhang C, Zhang J, Cheng Q, et al. CTLs heterogeneity and plasticity: implications for cancer immunotherapy. Mol Cancer. 2024Mar 21;23(1):58.","journal-title":"Mol Cancer"},{"key":"4183_CR61","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fonc.2016.00233","volume":"6","author":"M Swart","year":"2016","unstructured":"Swart M, Verbrugge I, Beltman JB. Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. Front Oncol. 2016;6:233.","journal-title":"Front Oncol"},{"issue":"4","key":"4183_CR62","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.eururo.2020.07.011","volume":"78","author":"NJ Salgia","year":"2020","unstructured":"Salgia NJ, Bergerot PG, Maia MC, Dizman N, Hsu J, Gillece JD, et al. Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti-PD-1 Immune Checkpoint Inhibitors. Eur Urol. 2020Oct;78(4):498\u2013502.","journal-title":"Eur Urol"},{"issue":"2","key":"4183_CR63","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00060-22","volume":"37","author":"A Yadegar","year":"2024","unstructured":"Yadegar A, Bar-Yoseph H, Monaghan TM, Pakpour S, Severino A, Kuijper EJ, et al. Fecal microbiota transplantation: current challenges and future landscapes. Clin Microbiol Rev. 2024Jun 13;37(2): e0006022.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"4183_CR64","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2174\/1874467215666220222105004","volume":"16","author":"LA Ahmed","year":"2023","unstructured":"Ahmed LA, Al-Massri KF. Gut Microbiota Modulation for Therapeutic Management of Various Diseases: A New Perspective Using Stem Cell Therapy. Curr Mol Pharmacol. 2023;16(1):43\u201359.","journal-title":"Curr Mol Pharmacol"},{"key":"4183_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102787","volume":"129","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Chen J, Liu H, Dai J, Zhao J, Zhu S, et al. The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Cancer Treat Rev. 2024Sep;129: 102787.","journal-title":"Cancer Treat Rev"},{"key":"4183_CR66","doi-asserted-by":"crossref","unstructured":"Halsey TM, Thomas AS, Hayase T, Ma W, Abu-Sbeih H, Sun B, et al. Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis. Sci Transl Med. 2023 Jun 14;15(700):eabq4006.","DOI":"10.1126\/scitranslmed.abq4006"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04183-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04183-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04183-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T19:02:10Z","timestamp":1749409330000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04183-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4183"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04183-y","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate."}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"341"}}